← Leaderboards
Michael Joseph Bond
Yale University
$214,935
Attributed
$214,935
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $73.8K · FY2018–25$100K$75K$50K$25K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$214,935 · 2
By mechanism
F31$119,780 · 1
F32$95,155 · 1
Top collaborators
No co-investigators on record.
Most similar at Yale University
Same institution · by research overlap
- Craig M Crews$33,790,660
- Joan A. Steitz$10,021,081
- Roel Gw Verhaak$8,014,607
- Daniel Bondeson$452,479
- Allison Louise Didychuk$2,047,361
Others in their field
Other Emerging Leaders on “Malignant Neoplasms”
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
- Leonard Freedmand · Leidos Biomedical Research, Inc.$108,968,336
- Beverly Hayes · Leidos Biomedical Research, Inc.$98,336,166
- Martha Hering · Westat, Inc.$57,098,843
Research focus
Malignant NeoplasmsEventLibrariesProteinsGenesCellsFutureIn VivoMonitorTumorComplexGrowthBindingAffinityDimerBase5&AposCytotoxicityDimerizationCancer Testis AntigenCancer PatientAssay DevelopmentCancer TherapyCancerous
Grant awards (5)
Investigating IGF2BP1 as a novel Therapeutic Target for Ewing Sarcoma$21,327
F32 · FY2025 · CA · contact PI
Investigating IGF2BP1 as a novel Therapeutic Target for Ewing Sarcoma$73,828
F32 · FY2024 · CA · contact PI
Development of a Tumor-Specific PROTAC$30,240
F31 · FY2020 · CA · contact PI
Development of a Tumor-Specific PROTAC$45,016
F31 · FY2019 · CA · contact PI
Development of a Tumor-Specific PROTAC$44,524
F31 · FY2018 · CA · contact PI